COVID-19
Specialised Therapeutics CEO Carlo Montagner has appeared on a national business program, discussing the potential impact of the COVID-19 crisis on the global pharma supply chain, and the race for an effective COVID-19 vaccine and therapy.
He told business journalist Ahron Young that ST’s Spanish partner PharmaMar is now fast-tracking trials of its myeloma compound as an anti-COVID-19 agent, with laboratory tests delivering highly promising results. Mr Montanger says Australian pharmaceutical companies have sufficient inventories for the next six to nine months, warning that logistics and supply deliveries must be considered essential services. Click on the video banner above for more.